We also recognise that CCs may undergo epithelial–mesenchymal transition (EMT) and subsequently loose epithelial markers particularly EpCAM; therefore, it is important in future studies to further characterise the pool of circulating cancer-associated cells using mesenchymal markers such as Vimentin, Fibronectin or N-Cadherin. This evidence concerns the gene FN1 and cancer.